Strattera Related Published Studies
Well-designed clinical trials related to Strattera (Atomoxetine)
Does atomoxetine improve executive function, inhibitory control, and
hyperactivity? Results from a placebo-controlled trial using quantitative
measurement technology. [2012]
A randomized double-blind study of atomoxetine versus placebo for
attention-deficit/hyperactivity disorder symptoms in children with autism
spectrum disorder. [2012]
Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. [2011.12]
Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. [2011.10.21]
Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. [2011.06]
Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. [2011.06]
Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. [2011.05.11]
Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. [2011.05.01]
Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers. [2011.05.01]
Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. [2011.05]
Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. [2011.04]
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. [2011.04]
A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. [2011.04]
Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. [2011.03]
A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. [2011.02]
Effect of atomoxetine on executive function impairments in adults with ADHD. [2011.02]
Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine. [2011.01]
Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial. [2011]
A double-blind, placebo-controlled study of atomoxetine in young children with
ADHD. [2011]
Once-daily treatment with atomoxetine in adults with
attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind,
placebo-controlled trial. [2011]
Effect of atomoxetine on executive function impairments in adults with ADHD. [2011]
A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. [2010.11]
Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. [2010.11]
Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. [2010.09]
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. [2010.08.03]
Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients. [2010.08]
Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. [2010.06]
Atomoxetine's effect on societal costs in Sweden. [2010.05]
Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. [2010.01.30]
Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. [2010.01]
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson
disease. [2010]
Effects of atomoxetine on self-reported high-risk behaviors and health-related
quality of life in adolescents with ADHD. [2010]
Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity
disorder in adolescents with substance use disorder. [2010]
Genetic polymorphisms in the treatment of depression: speculations from an
augmentation study using atomoxetine. [2010]
Effect of Atomoxetine on Executive Function Impairments in Adults With ADHD. [2009.12.21]
Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. [2009.12]
Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder. [2009.12]
A randomized controlled trial of atomoxetine in generalized social anxiety disorder. [2009.12]
Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. [2009.12]
Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. [2009.12]
Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. [2009.11]
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. [2009.10]
Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. [2009.10]
Atomoxetine for freezing of gait in Parkinson disease. [2009.09.15]
Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. [2009.09]
Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. [2009.09]
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). [2009.08]
Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. [2009.07.01]
Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. [2009.06]
Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. [2009.05]
Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. [2009.04.01]
A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. [2009.04]
Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. [2009.04]
Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. [2009.03]
Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. [2009.02]
Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. [2009.02]
Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. [2009]
Atomoxetine attenuates dextroamphetamine effects in humans. [2009]
Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. [2008.11]
Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. [2008.09.15]
Abuse liability assessment of atomoxetine in a drug-abusing population. [2008.05.01]
Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. [2008.02]
A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. [2008.02]
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. [2007.11.01]
High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. [2007.09]
Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. [2007.09]
A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. [2007.08]
Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. [2007.08]
Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. [2007.07]
Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD. [2007.07]
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. [2007.04]
Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. [2007.03.01]
Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. [2007.03]
A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. [2007.02]
Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. [2007.01]
Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. [2006.12]
Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. [2006.12]
Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. [2006.11]
Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. [2006.10]
Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. [2006.04]
Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. [2006.03]
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. [2006.03]
A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. [2006.02]
Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. [2005.10]
Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. [2005.09]
Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. [2005.08]
Emotional dysregulation in adult ADHD and response to atomoxetine. [2005.07.15]
A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. [2005.07]
[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents] [2005.05]
Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants. [2005.05]
Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. [2005.03]
Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. [2005.03]
Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. [2004.10]
Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. [2004.07]
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. [2004.07]
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. [2004.02]
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. [2003.01.15]
Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. [2002.12]
Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. [2002.12]
Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. [2002.11]
Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. [2002.07]
|
